---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-021281"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T17:38:15.325964+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AcelRx reclassifies DSUVIA as discontinued in FY2022 10-K after March 2023 asset sale to Alora

## Summary
- On March 12, 2023, AcelRx sold DSUVIA/DZUVEO assets to Vertical Pharmaceuticals (Alora) and classified the business as discontinued from Q1 2023.
- 2022 Form 10-K MD&A and financial statements restated to show DSUVIA as discontinued operations for all periods presented.
- Continuing operations exclude DSUVIA; remaining business includes Zalviso, other pipeline, and collaboration revenue.
- Restatement aligns with discontinued operations presentation in Q1 2023 10-Q; no other changes to 2022 10-K.
- Cash, equivalents, and investments totaled $17.7M at December 31, 2022 (per restated balance sheet).

## SEC filing metadata
- accession: 0001437749-23-021281
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774923021281/0001437749-23-021281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774923021281/acrx20230717_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-021281
- JSON: https://secwatch.observer/filing/0001437749-23-021281.json
- Plain text: https://secwatch.observer/filing/0001437749-23-021281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.